LifeMD Misses Q2 Revenue, Slashes 2026 Guidance on GLP-1 Shift
LFMD sits 33% above its 52-week low of $2.56 on elevated volume (1.9× avg).
Summary
LifeMD's Q2 revenue fell short of estimates at $47.3M, and adjusted EBITDA loss widened to -$3.5M, missing consensus by a wide margin. The company blamed a transition from compounded to branded GLP-1 therapies, which reduced upfront revenue. Gross margin improved to 89%, but the top-line miss and guidance cut overshadow it. Full-year 2026 revenue guidance was slashed to $205.5M-$212.5M from $220M-$230M, signaling a slower recovery. This follows a Q1 net loss and debt covenant breach, adding to financial stability concerns. Active subscribers grew 20% YoY, but the near-term outlook remains pressured. Q3 guidance of $48M-$51M revenue and adjusted EBITDA between -$1M and +$2M will be the next checkpoint.
At the time of this announcement, LFMD was trading at $3.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $178M. The 52-week trading range was $2.56 to $12.72. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.